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species (table I)'. Serum (rose bengal-positive, Wright 1:160, im-
munofluorescence 1:160) and CSF (rose bengal-positive, im-
munofluorescence 1:64) Brucella serology were positive and the
patient was treated with daily rifampin, 900 mg, plus doxycycline,
200 mg, for 8 weeks with complete recovery.
Brucellosis and tuberculosis are still endemic in our country. When
the central nervous system is involved, the clinical picture and CSF
analysis (elevation of protein, decreased glucose, and lymphocytic
pleocytosis) may appear similar [6]. Fortunately, CSF and blood se-
rology in neurobrucellosis are rarely negative, especially when a
complete battery of tests is available, such as rose bengal and Wright
agglutination, Coombs' test, and indirect immunofluorescence (as
is the case in our hospital) or ELISA [7]. However, in the absence
of these examinations, a correct diagnosis may be difficult [8].
Increased (>9 units/l) ADA in CSF has been reported to have a
sensitivity of 1 and specificity of O.99 in the diagnosis of tuberculous
meningitis [9]. However, patients with neurobrucellosis were not
included in the control groups. False-positive results have been
reported in cases of purulent meningitis [9, 10], but that condition
could hardly be confused with tuberculous meningitis. However,neu-
robrucellosis can easily be mistaken for tuberculous meningitis.
On the basis of our data, we think that physicians in countries
where brucellosis and tuberculosis are endemic should take care when
interpreting increased ADA in CSF, at least until neurobrucellosis
can be definitively excluded.
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The Hyperreactive Malarial Splenomegaly Syndrome
in a European: Has the Treatment a Modulatory
Effect on the Immune System?
COLLEAGUEs-The hyperreactive malarial splenomegaly (HMS) syn-
drome, also known as tropical splenomegaly syndrome, is believed
to represent an aberrant immunologic response to repeated malarial
infections and occurs in adultlong-term residents of malarious areas.
The syndrome is characterized by a gross splenomegaly with hyper-
splenism, high titers of malarial IgM antibodies, a high polyclonal
IgM level, hepatic and medullary lymphocytic proliferation, and nor-
mal phytohemagglutination response oflymphocytes [1]. We report
a case of HMS syndrome in a white male patient once a resident
of Madagascar.
A 60-year-old Swiss man had lived for 30 years in Madagascar.
He had taken antimalarial prophylaxis (chloroquine) irregularly. In
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1983 he gave a history of malaria which was treated by Fansidar
(Roche, Basel, Switzerland). At this time the spleen was not enlarged.
At the end of 1986 the complaints were tiredness, anorexia (loss of
5 kglyear), fever, and malaise. There was no history of alcoholism
or jaundice. In 1987 he returned to Switzerland; 2 months later he
did not feel any improvement and therefore was hospitalized. On
examination he looked pale, his weight was 73 kg, and his height
173 cm. During the hospitalization he was never febrile. The liver
was not enlarged, but the spleen wastender and the lower edge reached
the umbilicus. There were no stigmata of liver disease or other ab-
normal physical signs.
Laboratory findings included a hemoglobin concentration of 78 gil
(mean corpuscular volume, 85 fl; mean corpuscular hemoglobin,
31 pg), white blood cell count of 2.8 x 109/1 (neutrophils 49%,
lymphocytes 45 %, monocytes 3.5%, eosinophils 1%), and throm-
bocytes diminished to 113 x 109/1. Erythrocyte sedimentation rate
(ESR) was 130 mm/h. Plasma urea, creatinine, electrolytes, and liver
function tests were all in the normal range. The proteins were 91 gil.
Electrophoresis showed raised immunoglobulins without monoclo-
nal spike: serum IgG, 31 (normal, 8-18) g/I; IgA, 1.1 (0.7-4) gil;
and IgM, 14.7 (0.7-2.8) gil.
Blood smears for malarial parasites were negative several times.
No abnormalities or parasites were found in the stool or urine. Anti-
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body tests for cytomegalovirus, chlamydia, Epstein-Barr virus, toxo-
plasma, schistosoma, and brucella were negative. The malarial
antibody titers (IF!, Tropical Institute, Basel, Switzerland) for plas-
modium falciparum and vivax were 1:5120. Sonography and com-
puted tomography of the abdomen confirmed the splenomegaly
(24 x II ern, 2400 em'). A liver biopsy showed marked sinusoi-
dal infiltration with lymphocytes but no malarial pigment. Bone mar-
row examination showed a hyperplasia of the erythroid cells and an
excess of lymphocytes. No evidence of any malignant cells or pig-
ments was seen.
Thus, the patient presented a typical picture of HMS syndrome.
No improvement could be seen during the first 2 months after his
return from Madagascar to Switzerland, so we introduced antimalarial
treatment at a prophylactic dose (chloroquine, 300 mg/week). The
patient soon began to feel well and had no further complaints. The
spleen diminished progressively, the ESR fell almost to the normal
range, and the pancytopenia disappeared (figure I).
This is the first case, to our knowledge, of a white male patient
meeting the accepted criteria of HMS syndrome. It was previously
not known if this illness would strike only the population of tropical
countries. Different factors play an important part in the pathogene-
sis of this syndrome: a long period of exposure to malaria, the an-
timalarial drug prophylaxis [2], and a genetic or environmental
predisposition [3, 4]. The association of antigens and haplotypes of
HLA-DRZ was found to be more frequent in patients suffering from
gross splenomegaly than in those with moderate splenic enlarge-
ment [5]. It is still not known whether a European would have the
same aberrant immunologic response.
Two cases that could correspond to HMS syndrome in Europeans
have been reported. The first, a Caucasian residing in Africa, showed
all the criteria except the high IgM level, which was not measured
[6]. The high IgM level (at least 2 SD above the local mean) allows
differential diagnosis from other splenomegalies [2]. Although en-
largement ofthe spleen (minimal at 10 em below the costal margin)
is a major criterion of this syndrome [2], the second published case
in a European [7] reported a barely palpable spleen. Those authors
believed that the irregular antimalarial prophylaxis was the cause
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of the minimal enlargement. However, our case meets all the criteria
of HMS syndrome.
Studies explaining the pathogenesis indicate that serum samples
from patients with HMS syndrome contain lymphocytotoxic anti-
bodies (lgM) triggered by repeated or persistent exposure to malar-
ial parasites with specificity for 1'8+ suppressor lymphocytes, thus
leaving relatively unopposed the stimulating effect of helper T lym-
phocytes on B cells [8]. The high level of B cell activity explains
the production of protein in high concentrations. The treatment con-
sists in the inhibition of the triggering mechanism of IgM produc-
tion. Antimalarial therapy (in prophylactic dose) is usually followed
by disappearance of the symptoms [2].
As blood smears for malarial parasites were negative several times
and as our patient was never febrile, we were interested to see his
spontaneous course in the absence of new malarial infection in Swit-
zerland. Because he felt no improvement during the first 2 months,
administration of chloroquine, in an antimalarial prophylactic dose,
was necessary. This treatment induced a progressive disappearance
of the clinical and laboratory signs.
Chloroquine seems to have a modulatory effect on the immune
system. In addition to our case, studies recently published [9] show
that this drug in doses recommended for malarial prophylaxis reduces
the antibody response to primary immunization with intradermal
human diploid-cell rabies vaccine. These results are explained by
the impaired secretion of a lymphocyte-activatingfactor, interleukin-l
[10]. However, the precise mechanism of chloroquine activity is not
known, and further studies are necessary to understand the effect
of this drug on the immune system in HMS syndrome.
D. C. Betticher, A. Nicole, P. Pugin, and C. Regamey
Clinique Medicale, Hopital Cantonal, Fribourg, Switzerland
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Figure 1. Evolution of splenic volume, hemo-
globin (Hb) concentration, and erythrocyte
sedimentation rate (ESR) after administration
of chloroquine.
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New and Old Drugs for Treating Typhoid Fever
COLLEAGUEs-Typhoid fever continues to bea common public health
problem and a significant cause of morbidity and mortality in many
parts of the world. Despite the excellent in vitro activity of many
antibiotic drugs against Salmonella species, the clinical efficacy of
some is unclear and others are now being evaluated. Thus, the best
treatment remains controversial as evidenced by several studies re-
cently published in the Journal (1-3]. These studies demonstrated
the clinical efficacy of some third-generation cephalosporins and
quinolones in the treatment of typhoid fever. The authors suggested
that these new drugs may be a good alternative to chloramphenicol,
which is cited in all of these studies as remaining the drug of choice
for treatment of typhoid fever. Althou~h most clinicians will agree,
we are uncertain that a definitive study of chloramphenicol in the
treatment of typhoid fever has been carried out.
The renewed interest in the clinical efficacyof new drugs for treating
typhoid is justified mainly by the potentially dangerous side effects
of chloramphenicol and the data derived from studies showing that
ampicillin is not as active as chloramphenicol, We recently reviewed
several studies published many years ago [4-7] and observed that
inadequate dosage and route of administration of ampicillin could
have been responsible for these less favorable results. In fact, more
recent studies have shown that intravenous ampicillin in high doses
(150-200mg/kg/day) is highlyeffectivein treating typhoid fever [8, 9].
During a recent outbreak of typhoid fever in Israel, we compared
the clinical efficacy of chloramphenicol with high-dose intravenous
ampicillin [10]. Our results not only confirmed the above-mentioned
data but also showed a more rapid defervescence and a lower re-
lapse rate with this ampicillin regimen. We think that this less toxic
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drug, which has all of the advantages of chloramphenicol such as
clinical efficacy and oral availability (for continuing treatment after
defervescence occurs), should be considered in the treatment of ty-
phoid fever. Certainly it is a less expensive alternative for the public
health systems of developing countries.
Renato Finkelstein and Arie Markel
Infectious Diseases Unit and Department of Internal Medicine.
Rambam Medical Center, Haifa. Israel
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